{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Toxicity and Intensity', 'Supportive Care and Selinexor Dose Adjustment Guidelines', 'Tumor lysis syndrome', 'If TLS risk factors are identified, provide prophylactic IV hydration and regular monitoring of hydration', '(especially when increasing the dose of selinexor), renal function, urine output, and clinical laboratory measures', 'of interest for TLS (eg, phosphorus, potassium, calcium, LDH, uric acid). Consider administration of', 'hypouricemic agents to reduce the risk of TLS.', 'Interrupt selinexor in patient with hyperkalemia (7.0 mmol/L) and/or symptoms of hyperkalemia, an increase in', 'uric acid, or other changes in biochemical blood parameters suggestive of TLS. Start IV hydration and consider', 'hypouricemic agent until levels return to normal. Selinexor can be reintroduced at the normal or reduced dose.', 'Other selinexor-related adverse events', 'Grade 1 or 2', 'Rule out other causes. Maintain dose. Start treatment and/or standard', 'supportive care per institutional guidelines.', 'Grade 3 or 4', 'Rule out other causes. Interrupt selinexor until recovers to Grade 2 or', 'baseline and reduce selinexor by 1 dose level.', 'Isolated values of Grade >3 alkaline phosphatase do NOT require dose', 'interruption. Determination of liver versus bone etiology should be made,', \"and evaluation of gamma-glutamyl transferase, 5'-nucleotidase, or other\", 'liver enzymes should be performed.', 'Abbreviations: IV = intravenous; LDH = lactate dehydrogenase; NCCN = National Comprehensive Cancer', 'Network; QD = once daily; PO = oral; SC = subcutaneous: TLS = tumor lysis syndrome.', 'a For all Grade >3 hematologic or non-hematologic AEs that are NOT selinexor related, after consultation with the', 'Medical Monitor and at the discretion of the Investigator, selinexor dosing may be maintained.', 'b', \"For all selinexor-related AE's, if the below prescribed dose reductions/interruptions result in a stabilization of\", '>4 weeks, a re-escalation may be considered after approval from the Medical Monitor.', 'All dose modifications should be based on the worst preceding toxicity.', 'Note: When toxicities due to selinexor have returned to baseline levels or the patient has stabilized, the dose of', 'selinexor may be re-escalated in consultation with the Medical Monitor.', 'Additional recommendations for supportive care to help manage selinexor-related AEs are', 'provided in Section 10.3.2.', 'The possibility of overlapping toxicities with bortezomib and/or dexamethasone should be', 'considered and it is strongly recommended that the Investigator dose reduces or interrupts 1 drug', 'at a time (see Section 10.4.2).', '10.4.1.1. Selinexor Dose Adjustment in the Setting of Infection', 'Patients with active uncontrolled or suspected infections should have treatment withheld until the', 'infection has clinically resolved and/or the patient is clinically stable. When ready to resume', 'dosing, treatment may continue at the original dose. Missed doses will not be replaced. Patients', 'may continue on antibiotics for prolonged periods while re-initiating their treatment at the', 'discretion of the Investigator.', '10.4.1.2. Conditions Not Requiring Selinexor Dose Reduction', 'The following conditions are exceptions to the dose-modification guidelines. Selinexor does not', 'need to be interrupted in the following cases:', 'Alopecia of any grade', 'Electrolyte or serum analyte (eg, urate) abnormalities that are reversible with standard', 'interventions', 'Confidential', 'Page 67', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Isolated values of Grade >3 alkaline phosphatase. Determination of liver versus bone', 'etiology should be made, and evaluation of gamma-glutamyl transferase,', \"5'-nucleotidase, or other liver enzymes should be performed.\", '10.4.2.', 'Dose Modifications for Overlapping Toxicities', 'Thrombocytopenia and neutropenia are potential overlapping toxicities for selinexor with', 'bortezomib. If a patient experiences drug-induced thrombocytopenia and/or neutropenia while', 'receiving the combination under investigation in this study, the Investigator should attempt to', 'determine which drug may be responsible and treat appropriately, including dose modifications,', 'as necessary. If, during the management of an AE for an individual patient receiving both', 'selinexor and bortezomib, the Investigator suspects that bortezomib may be the cause of that', 'event, the Investigator should discuss the case with the Medical Monitor. If the cause cannot be', 'attributed to a single drug, it is strongly recommended that the Investigator dose reduces or', 'interrupts 1 drug at a time. Please refer to Table 16 for AEs presumed to be related to selinexor.', 'The manufacturers of bortezomib have provided dose adjustment guidelines for managing', 'Grade 3 to 4 thrombocytopenia and neutropenia that occur during treatment with bortezomib in', 'the prescribing information.', '10.4.3.', 'Bortezomib Dose Modifications', 'In the event of bortezomib-related peripheral neuropathy (Grade 1 with pain or Grade', '2', '[moderate symptoms; limiting instrumental activities of daily living]), during treatment with', '1.3 mg/m\u00b2 bortezomib BIW, change treatment schedule to 1.3 mg/m\u00b2 bortezomib QW.', 'For all other bortezomib-related events, the bortezomib dose may be adjusted during treatment', 'according to the guidelines in the prescribing information for bortezomib (different', 'local/regional trade names may be used).', '10.4.4.', 'Dexamethasone Dose Modifications', 'The dose of dexamethasone should preferably remain constant throughout the study.', 'However, for patients with partial intolerance to dexamethasone, a dose reduction to a minimum', 'dose of 10 to 12 mg dexamethasone BIW (ie, a total minimum dose of 20 to 24 mg weekly) is', 'permitted after a clear documentation of intolerance. Any dose reductions should be documented', \"in the patient's research record and the eCRF.\", '10.5.', 'Missed or Vomited Doses', '10.5.1.', 'Missed Doses of Study Treatments (Selinexor, Bortezomib, and Dexamethasone)', 'Missed doses of study treatments should be managed as follows:', 'For doses missed for protocol- or study-related reasons (eg, due to recommendation of the', 'Investigator, such as due to an AE):', 'Missed dose of bortezomib for patients in the Vd Arm Only: If a bortezomib dose', 'was missed, the schedule of that week should be altered to accommodate 2 doses in', 'that week with at least 72 hours between 2 consecutive doses of bortezomib.', 'Confidential', 'Page 68', 'Version 4.0']\n\n###\n\n", "completion": "END"}